Higher Integrin Alpha 3 Beta1 Expression in Papillary Thyroid Cancer Is Associated with Worst Outcome
by
, , , and
Lorenza Mautone
1,†
,
Carlo Ferravante
1,2,†,
Anna Tortora
1,
Roberta Tarallo
1,
Giorgio Giurato
1,
Alessandro Weisz
1,3,*
and
Mario Vitale
1,* 1
Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy
2
Genomix4Life, 84081 Baronissi, Italy
3
Genome Research Center for Health-CRGS, University of Salerno Campus of Medicine, 84081 Baronissi, Italy
*
Authors to whom correspondence should be addressed.
†
Both authors contributed equally to this work.
Cancers 2021, 13(12), 2937; https://doi.org/10.3390/cancers13122937
Submission received: 19 May 2021
/
Revised: 2 June 2021
/
Accepted: 7 June 2021
/
Published: 11 June 2021
(This article belongs to the Special Issue Thyroid Cancers)
Simple Summary
Integrins are cell-extracellular matrix adhesion molecules considered functionally related to the development of cancer metastasis. Starting from a large dataset of mRNA-seq of papillary thyroid carcinoma (PTC), we investigated the potential role of integrins in the clinical course of PTC patients. Results showed that the PTC “classical” and “tall cell” histology variants display a more similar integrin expression profile with respect to the ‘follicular’ variant. Interestingly, the BRAFV600E mutation was found to be associated with a higher expression of integrins compared to RAS mutations. The integrin subunit ITGA3 was associated with advanced disease stage, lymph node metastasis, extrathyroidal extension, high-risk, and a worst prognosis. In vitro assays with PTC cell lines demonstrated the role of the α3β1 integrin in cell motility and invasion, evidence that supports the role of this adhesion molecule in tumor progression. These results demonstrate the existence of a PTC-specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease.
Abstract
Integrins are cell-extracellular matrix adhesion molecules whose expression level undergoes quantitative changes upon neoplastic transformation and are considered functionally related to the development of cancer metastasis. We analyzed the largest mRNA-seq dataset available to determine the expression pattern of integrin family subunits in papillary thyroid carcinomas (PTC). ITGA2, 3, 6, V, and ITGB1 integrin subunits were overexpressed in PTC compared to normal thyroid tissue. The PTC histology variants “classical” and “tall cell” displayed a similar integrin expression profile with a higher level of ITGA3, ITGAV, and ITGB1, which differed from that of the “follicular” variant. Interestingly, compared to RAS mutations, BRAFV600E mutation was associated with a significantly higher expression of integrins. Some integrin subunits were associated with advanced disease stage, lymph node metastasis, extrathyroidal extension, and high-risk groups. Among them, ITGA3 expression displayed the highest correlation with advanced disease and was associated with a negative prognosis. In vitro scratch assay and Matrigel invasion assay in two different PTC cell lines confirmed α3β1 role in cell motility and invasion, supporting its involvement during tumor progression. These results demonstrate the existence of a PTC-specific integrin expression signature correlated to histopathology, specific driver gene mutations, and aggressiveness of the disease.
Keywords:
integrins; thyroid cancer; BRAF mutation
